You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CART19

Showing 1 - 25 of 336
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)

Withdrawn
  • Acute Lymphoblastic Leukemia
  • +2 more
  • PACE CART19
  • (no location specified)
Mar 9, 2022

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed

Recruiting
  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous CAR19 T lymphocytes
  • Prague, Czechia
    Institute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022

Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

Not yet recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoma, Non-Hodgkin
  • CART-19
  • Ribeirao Preto, Sao Paulo, Brazil
    Ribeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With CNS

Active, not recruiting
  • Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
  • +2 more
  • Murine CART19
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 11, 2022

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART

Active, not recruiting
  • Multiple Myeloma
  • BCMA CART + huCART19
  • +2 more
  • Philadelphia, Pennsylvania
    Univ. of Pennsylvania
Jul 11, 2022

Lymphoblastic Leukemia, Acute, Childhood Trial in Philadelphia (Tocilizumab, CART 19)

Completed
  • Lymphoblastic Leukemia, Acute, Childhood
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jun 30, 2021

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Colorectal Cancer Trial in United States (GCC19CART)

Recruiting
  • Colorectal Cancer
  • San Francisco, California
  • +4 more
Dec 20, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

FDG-PET/CT Imaging as Early Predictor of DP

Completed
  • Lymphoma
  • There is no intervention
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 7, 2022

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Systemic Lupus Erythematosus Trial in Shanghai (Relma-cel)

Recruiting
  • Systemic Lupus Erythematosus
  • Relma-cel
  • Shanghai, China
    Relma-cel Medical
Mar 12, 2023

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • ARI0003
  • Santiago De Compostela, A Coruña, Spain
  • +6 more
Oct 24, 2023

Acute Lymphoid Leukemia Trial in Spain (ARI-0001 cells)

Recruiting
  • Acute Lymphoid Leukemia
  • ARI-0001 cells
  • Badalona, Barcelona, Spain
  • +9 more
Feb 3, 2022

SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy

Recruiting
  • Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
  • COVID-19 serology IgG
  • Detroit, Michigan
    Henry Ford Health System
Jul 19, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

Unknown status
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 30, 2021